Bryn Mawr Trust »

Rapport Therapeutics shares owned by Bryn Mawr Trust

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Bryn Mawr Trust from 13F filings

Historical chart of Bryn Mawr Trust investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Bryn Mawr Trust consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Bryn Mawr Trust

Quarter filed Position value Share count Share price at filing
2025-09-30 $143k 4.8k 29.70

More positions owned by Bryn Mawr Trust

Comcast Corp Cl A (CMCSA)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Ishares Tr Rus Tp200 Gr Etf (IWY)
Ishares Tr Core S&p500 Etf (IVV)
JPMorgan Chase & Co. (JPM)
Vanguard Index Fds Total Stk Mkt (VTI)
Ishares Tr Msci Usa Qlt Fct (QUAL)
Johnson & Johnson (JNJ)
Alphabet Cap Stk Cl C (GOOG)
Ishares Tr Eafe Sml Cp Etf (SCZ)
Berkshire Hathaway Inc Del Cl A (BRK.A)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Procter & Gamble Company (PG)

View all positions for Bryn Mawr Trust

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
Sofinnova Ventures
Johnson & Johnson
Vanguard Group
BlackRock
Baker Bros. Advisors
Siren
Trv Gp Vi
Vestal Point Capital
Polar Capital Holdings

View all funds holding Rapport Therapeutics